BCRX241220P4000
- 0.30
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharma Analyst Ratings
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
BioCryst Pharmaceuticals Price Target Raised to $16.00/Share From $15.00 by JMP Securities
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30
Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $7
BioCryst Pharmaceuticals: A Buy Rating Anchored on Orladeyo's Success and Expansion in Rare Disease Treatments
BioCryst Pharma Analyst Ratings
BioCryst Pharmaceuticals: Strong Orladeyo Sales and Promising Pipeline Justify Buy Rating
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $20
BioCryst (BCRX) Receives a Buy From RBC Capital
BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings